Physician profile
Eiran Gorodeski
NPI 1396729943
$33,683.66
in general payments reported to CMS, 2019-2025
25 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,772 · 2021: $183 · 2022: $2,487 · 2023: $3,324 · 2024: $413 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,968 · Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,968.00 |
| Food and Beverage | $1,527.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27,166.82 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Masimo Corporation | $3,071.78 | 2022-2023 | Sedline, Rainbow Acoustic Monitoring |
| Boston Scientific Corporation | $2,308.19 | 2022 | |
| Edwards Lifesciences Corporation | $157.45 | 2023 | |
| Medtronic, INC. | $131.81 | 2023 | Avalus |
| Medtronic Vascular, INC. | $125.97 | 2020 | |
| Alnylam Pharmaceuticals INC. | $119.22 | 2024-2025 | Onpattro |
| Pfizer INC. | $73.89 | 2019-2025 | |
| Abiomed | $65.83 | 2022-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.60 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $60.55 | 2020-2025 | Nexletol |
| Bridgebio Pharma, INC. | $52.24 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $48.17 | 2025 | Farxiga, Wainua |
| Atricure, INC. | $36.80 | 2023-2025 | Synergy Ablation System |
| E.R. Squibb & Sons, L.L.C. | $36.16 | 2025 | Camzyos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $29.42 | 2025 | Kengreal |
| Novartis Pharmaceuticals Corporation | $23.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2025 | |
| Amgen INC. | $19.09 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.44 | 2021 | |
| Genzyme Corporation | $15.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.53 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.67 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.78 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eiran Gorodeski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.